↓ Skip to main content

Dove Medical Press

Article Metrics

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

Overview of attention for article published in Drug Design, Development and Therapy, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#44 of 1,137)
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
1 news outlet
wikipedia
1 Wikipedia page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
52 Mendeley
Title
Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
Published in
Drug Design, Development and Therapy, January 2017
DOI 10.2147/dddt.s104227
Pubmed ID
Authors

Ádám Annus, László Vécsei

Abstract

Parkinson's disease (PD) is a progressive, chronic, neurodegenerative disease characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symptoms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemical properties of opicapone, summarize its preclinical and clinical trials and discuss its future potential role in the treatment of PD.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 21%
Student > Bachelor 10 19%
Student > Ph. D. Student 4 8%
Student > Postgraduate 3 6%
Student > Master 3 6%
Other 9 17%
Unknown 12 23%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 9 17%
Medicine and Dentistry 8 15%
Biochemistry, Genetics and Molecular Biology 6 12%
Neuroscience 4 8%
Agricultural and Biological Sciences 3 6%
Other 6 12%
Unknown 16 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2017.
All research outputs
#1,026,385
of 9,665,907 outputs
Outputs from Drug Design, Development and Therapy
#44
of 1,137 outputs
Outputs of similar age
#49,664
of 315,274 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 42 outputs
Altmetric has tracked 9,665,907 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,137 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,274 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.